TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35093510

Group type: EXPERIMENTAL
Intervention: Phyllanthus Emblica (Amla)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study: 34295981

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (140 mg)
Number of subjects: 90
Study: 34866362

Group type: EXPERIMENTAL
Intervention: Six lncRNA-based signature
Number of subjects: 0
Study: 34065380

Group type: EXPERIMENTAL
Intervention: Saturated Fatty Acids (SFA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mono-Unsaturated Fatty Acids (MUFA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Medium-Chain Fatty Acids (MCFA)
Number of subjects: 13
Study: 32632078

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (12 weeks duration)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 34491371

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vitamin D deficiency or insufficiency
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vitamin D intake
Number of subjects: 12
Study: 32556768

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg/day intravenously for 3 days followed by 40 mg/day orally for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 20
Study: 35838130

Group type: EXPERIMENTAL
Intervention: Bipolar Needlescopic Enucleation of the prostate (BNEP)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Bipolar Vapoenucleation of the prostate (BVEP)
Number of subjects: 214
Study: 34297677

Group type: EXPERIMENTAL
Intervention: Active Breaks Program (20 periods of weekly ABs, 5-10 minutes, 3-5 times a day for 17 weeks)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no active breaks)
Number of subjects: 166
Study: 36102762

Group type: EXPERIMENTAL
Intervention: Senior Chef programme (SC group) - 8-week nutrition education and cooking class (3 hours weekly)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Steady As You Go programme (SAYGO group) - 10-week strength and balance exercise programme (1 hour weekly)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Combined SC and SAYGO intervention (combined group) - 10-week programme combining both interventions
Number of subjects: 468

Group type: COMPARATOR
Intervention: Social programme (control group) - 10-week seated group socialising activity (once a week)
Number of subjects: 468
Study: 33577011

Group type: EXPERIMENTAL
Intervention: Anti‐β2 glycoprotein I antibody IgA/G/M
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Platelet aggregation rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D‐dimer levels
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (33 healthy pregnant women)
Number of subjects: 60
Study: 32237143

Group type: EXPERIMENTAL
Intervention: Group game intervention including routine preoperative preparation and group game
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 94
Study: 35313733

Group type: EXPERIMENTAL
Intervention: Ablation-based rhythm control
Number of subjects: 411

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 411
Study: 33466137

Group type: EXPERIMENTAL
Intervention: Continuous nursing care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34056698

Group type: COMPARATOR
Intervention: Negative control (0 ppm F; no TMP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: F500 (500 ppm NaF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: F1500 (1500 ppm NaF-positive control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TMP (1% TMP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: F + TMP (500 ppm NaF + 1% TMP)
Number of subjects: 60
Study: 33315081

Group type: EXPERIMENTAL
Intervention: Home-visiting intervention
Number of subjects: 0
Study: 36436532

Group type: EXPERIMENTAL
Intervention: Exposure therapy with aerobic exercise (10 min aerobic exercise after nine 90‐min weekly sessions of exposure therapy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Exposure therapy with passive stretching (10 min passive stretching after nine 90‐min weekly sessions of exposure therapy)
Number of subjects: 130
Study: 35353186

Group type: EXPERIMENTAL
Intervention: Kyoto Prognostic Index (KPI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: International Prognostic Index (IPI)
Number of subjects: 58
Study: 33043351

Group type: EXPERIMENTAL
Intervention: All-ceramic micro-veneer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Minimally invasive ultra-thin veneer
Number of subjects: 120
Study: 32388690

Group type: EXPERIMENTAL
Intervention: TIMB video condition
Number of subjects: 153

Group type: COMPARATOR
Intervention: Comparison video condition
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study: 32184123

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 3 g intravenous infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL, 0.9% NaCl) intravenous infusion
Number of subjects: 14
Study: 35315512

Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionated radiation of 52.5 Gy in 15 fractions
Number of subjects: 62
Study: 33685854

Group type: EXPERIMENTAL
Intervention: Escape COVID‐19 serious game
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (standard IPC material)
Number of subjects: 295
Study: 35331007

Group type: EXPERIMENTAL
Intervention: Intensive BG control (target BG 80-130 mg/dL) for 72 hours
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Standard BG control (target BG 80-179 mg/dL) for 72 hours
Number of subjects: 1151
Study: 33142785

Group type: EXPERIMENTAL
Intervention: Elderly patients with liver cancer
Number of subjects: 80574

Group type: EXPERIMENTAL
Intervention: Elderly patients with lung cancer
Number of subjects: 80574

Group type: EXPERIMENTAL
Intervention: Elderly patients with cancer (overall)
Number of subjects: 80574

Group type: COMPARATOR
Intervention: Non-cancer patients (control group)
Number of subjects: 80574
Study: 36071520

Group type: EXPERIMENTAL
Intervention: artesunate–mefloquine (AS/MQ)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin–piperaquine (DHA/PPQ)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: atovaquone–proguanil (ATQ/PG)
Number of subjects: 211
Study: 34198463

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) system based on radiomics and clinical indices
Number of subjects: 107
Study: 34255417

Group type: EXPERIMENTAL
Intervention: ESCP Safe Anastomosis Intervention
Number of subjects: 4440

Group type: COMPARATOR
Intervention: Control (standard practice)
Number of subjects: 4440
Study: 32079968

Group type: EXPERIMENTAL
Intervention: Culturally adapted obesity prevention intervention program (Healthy Balance) for Latinx immigrant families.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Original and translated group intervention for a heterogeneous population.
Number of subjects: 92
Study: 35939332

Group type: EXPERIMENTAL
Intervention: AI-guided PVI
Number of subjects: 225

Group type: COMPARATOR
Intervention: CF-guided PVI
Number of subjects: 225
Study: 34273114

Group type: EXPERIMENTAL
Intervention: Miscanthus planted in tilled soil amended with organic P (Class B biosolids applied at 45 Mg ha‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Miscanthus planted in untilled soil, no amendments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Miscanthus planted in tilled soil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Miscanthus planted in tilled soil amended with inorganic P (triple superphosphate applied at 5:3 Pb:P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Existing vegetation
Number of subjects: 20
Study: 32948644

Group type: EXPERIMENTAL
Intervention: Postoperative AKI (Kidney Disease Improving Global Outcomes definition)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-AKI participants
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Children aged <2 years at surgery
Number of subjects: 124
Study: 34782191

Group type: EXPERIMENTAL
Intervention: Adjunctive oral dexamethasone
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 401
Study: 33060531

Group type: EXPERIMENTAL
Intervention: Routine hydration (1 ml/kg/h, 0.9% sodium chloride) for 3-12 hours before and 24 hours after contrast exposure
Number of subjects: 401

Group type: COMPARATOR
Intervention: Nonhydration (control group)
Number of subjects: 401
Study: 32187256

Group type: EXPERIMENTAL
Intervention: 200.000 IU of cholecalciferol (vitamin D)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 35110644

Group type: EXPERIMENTAL
Intervention: NeoRehab program (parent-provided interventions including vocal soothing, scent exchange, comforting touch, skin-to-skin care, massage, and physical therapy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: NeoRehab program
Number of subjects: 70
Study: 33892393

Group type: EXPERIMENTAL
Intervention: loadsol®
Number of subjects: 43
Study: 33829415

Group type: EXPERIMENTAL
Intervention: RadscoreFDG_T1WI_SWI model (optimal model comprising structural (T1WI), functional (SWI) and metabolic (18F-FDG) sequences)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clinical-radiomics integrated model (incorporating RadscoreFDG_T1WI_SWI, three clinical symptoms, and SUVmax)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clinical-radiomics integrated model
Number of subjects: 90
Study: 34363130

Group type: EXPERIMENTAL
Intervention: Smart wearable devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mobile app (Control)
Number of subjects: 0
Study: 32979235

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32270636

Group type: EXPERIMENTAL
Intervention: Jiaotong qiaomai needling technique of acupuncture
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine needling technique of acupuncture and rehabilitation exercise (Control)
Number of subjects: 64
Study: 35348584

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 144
Study: 34207794

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day)
Number of subjects: 417
Study: 35684956

Group type: EXPERIMENTAL
Intervention: Online cultural care training program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 36396531

Group type: EXPERIMENTAL
Intervention: Tungsten carbide bur (TCB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasonic scaler (US)
Number of subjects: 40
Study: 35202591

Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 941

Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 941
Study: 32046647

Group type: EXPERIMENTAL
Intervention: Stratified care using the Keele STarT MSK Tool
Number of subjects: 524

Group type: COMPARATOR
Intervention: Non-stratified care
Number of subjects: 524
Study: 35980648

Group type: EXPERIMENTAL
Intervention: Individualised management combined with drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individualised management combined with drug treatment
Number of subjects: 60
Study: 33307383

Group type: EXPERIMENTAL
Intervention: Universal‐Design‐symbol
Number of subjects: 346

Group type: COMPARATOR
Intervention: ISA
Number of subjects: 346

Group type: COMPARATOR
Intervention: Motion‐symbol
Number of subjects: 346

Group type: COMPARATOR
Intervention: All-symbols
Number of subjects: 346
Study: 32621144

Group type: EXPERIMENTAL
Intervention: Coronary CTA as a diagnostic tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine interventional strategy in addition to optimal medical therapy
Number of subjects: 0
Study: 33930204

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 80
Study: 33338035

Group type: EXPERIMENTAL
Intervention: Emphasis on the unequal aspect of the pandemic (focusing on the elderly and those with medical conditions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Language that emphasizes the impact of the virus on all of us
Number of subjects: 0
Study: 35843106

Group type: EXPERIMENTAL
Intervention: 20 g of fructooligosaccharide (FOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 g of partially hydrolyzed guar gum (PHGG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 g of digestible maltodextrin (placebo)
Number of subjects: 0
Study: 33470727

Group type: EXPERIMENTAL
Intervention: Daily financial incentives linked to real-time adherence monitoring
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 29
Study: 32333898

Group type: EXPERIMENTAL
Intervention: Satralizumab 120 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 35984917

Group type: EXPERIMENTAL
Intervention: Nurse-Led Symptom Management Program (NL-SMP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 41
Study: 33464762

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (1st line treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (2nd line treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32855201

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo surgery (diagnostic knee arthroscopy)
Number of subjects: 146
Study: 34896645

Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinic care
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 188
Study: 32746841

Group type: EXPERIMENTAL
Intervention: Occupation-based intervention supported with problem-solving therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 35449020

Group type: EXPERIMENTAL
Intervention: Tolvaptan (initial dose 7.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluid restriction (initial limit 1000 ml per 24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluid restriction
Number of subjects: 0
Study: 33815069

Group type: EXPERIMENTAL
Intervention: Repetitive peripheral nerve magnetic stimulation (rPNMS) at 20 Hz on the median nerve of the non-dominant hand.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham group (no stimulation output).
Number of subjects: 46
Study: 32299478

Group type: EXPERIMENTAL
Intervention: Victim Improvement Package (VIP)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 226
Study: 35390509

Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 884

Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 884
Study: 32921252

Group type: EXPERIMENTAL
Intervention: Minimal invasive extracorporeal circulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 60
Study: 32314298

Group type: EXPERIMENTAL
Intervention: Topical antifungal agent + CO2 laser ablation once a month for the first 3 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Topical antifungal agent
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Topical antifungal agent + CO2 laser ablation
Number of subjects: 160
Study: 34004077

Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 45
Study: 32965224

Group type: EXPERIMENTAL
Intervention: SMS text messages for drowning prevention
Number of subjects: 800
Study: 34465254

Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Hysterectomy (SILH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional Laparoscopic Hysterectomy (CLH)
Number of subjects: 50
Study: 33966560

Group type: EXPERIMENTAL
Intervention: BARKH-based algorithm for identification and treatment of hypertensive emergencies
Number of subjects: 0
Study: 32931137

Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 232

Group type: COMPARATOR
Intervention: Not having a defunctioning stoma (Control)
Number of subjects: 232
Study: 36146869

Group type: EXPERIMENTAL
Intervention: Loopdeetect COVID‐19
Number of subjects: 741

Group type: COMPARATOR
Intervention: RT-PCR Allplex 2019 n-Cov
Number of subjects: 741
Study: 34582281

Group type: EXPERIMENTAL
Intervention: Treatment seeking participants
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 281

Group type: COMPARATOR
Intervention: Non-treatment seeking participants
Number of subjects: 281
Study: 33038932

Group type: EXPERIMENTAL
Intervention: Integrated palliative care approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 35985097

Group type: EXPERIMENTAL
Intervention: Digital interventions targeting ED psychopathology
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Baseline positive body image constructs
Number of subjects: 600
Study: 33031782

Group type: EXPERIMENTAL
Intervention: SCORE intervention implemented after October 1, 2018
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Cancellations of orders
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Expired orders
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Scheduled orders
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Performed orders
Number of subjects: 447
Study: 32444309

Group type: EXPERIMENTAL
Intervention: SLOIT (slow low-dose oral immunotherapy)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (complete avoidance)
Number of subjects: 170
Study: 32812489

Group type: EXPERIMENTAL
Intervention: Counseling session, information booklet about DFV, and contact details of the counselor
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care plus a booklet containing contact details of local DFV support services
Number of subjects: 140
Study: 33798303

Group type: EXPERIMENTAL
Intervention: Baduanjin and auricular point sticking therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Estazolam 1 mg, once daily for 12 days
Number of subjects: 90
Study: 35511528

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 35262424

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study: 34658360

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy with alteplase in addition to routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy with alteplase in addition to routine therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 152
Study: 34283313

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Upfront surgery (pN3)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (CRT)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 196
Study: 34271194

Group type: EXPERIMENTAL
Intervention: Starvation for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Starvation for 0, 3 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Refeeding after starvation for 3 days
Number of subjects: 120
Study: 35105559

Group type: EXPERIMENTAL
Intervention: i²TransHealth internet-based health care programme for 4 months
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (waiting group)
Number of subjects: 163
Study: 34096012

Group type: EXPERIMENTAL
Intervention: Reduced ticagrelor maintenance dose with or without acetylsalicylic acid (ASA) withdrawal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose ticagrelor with dual antiplatelet treatment (DAPT)
Number of subjects: 0
Study: 33243764

Group type: EXPERIMENTAL
Intervention: Post-traumatic Stress Disorder Checklist (PTSD)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: 12‐Item General Health Questionnaire (CMDs)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: 5‐Item Dimensions of Anger Reactions‐Revised
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Social support and stressors related to COVID-19
Number of subjects: 1092
Study: 34584871

Group type: EXPERIMENTAL
Intervention: Traditional pediatric nursing teaching model combined with the humanistic care teaching model
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional pediatric nursing teaching model
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups after training
Number of subjects: 68
Study: 32145131

Group type: EXPERIMENTAL
Intervention: Peripheral nerve field stimulation (PNFS)
Number of subjects: 0
Study: 35980240

Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick, self-etch mode (CUQ-SE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etch adhesive) (CSEB)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tetric N-Bond Universal, etch-and-rinse mode (TBU-ER)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick, selective etch mode (CUQ-SLE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick, etch-and-rinse mode (CUQ-ER)
Number of subjects: 34
Study: 32755273

Group type: EXPERIMENTAL
Intervention: Cannabidiol (600 mg oral dose)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23